Full Press Release Details
Lexaria Files New Patent Application for Enhanced Transdermal
Kelowna, British Columbia March 20, 2018 Lexaria Bioscience
Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ), a drug delivery
platform innovator, is pleased to announce it has filed a new patent application
with the United States Patent and Trademark Office ( USPTO ) for use of
DehydraTECHTM to improve the speed and quantity of absorption of
active pharmaceutical ingredients ( API ) through the skin.
The patent application follows the recently announced
successful laboratory evaluation of DehydraTECHTM in the transdermal
delivery of cannabidiol ( CBD ) that showed as much as a 225% increase in CBD
permeability compared to control formulations tested with leading commercial
penetration enhancers; and almost a 1,900% increase in CBD permeability compared
to a control formulation that was devoid of both the DehydraTECHTM
technology or any commercial penetration enhancers. The original research
protocols were overseen by Lexaria President John Docherty and represent a
unique, new and improved method of transdermal delivery for cannabinoids and
potentially many other active ingredients.
In the patent application, Lexaria has applied for patent
protection for the delivery of all of the active ingredient classes already
identified in its other issued and pending patent applications including
cannabinoids, terpenes and terpenoids, NSAIDs, vitamins, nicotine and
phosphodiesterase inhibitors, as well as a broad range of additional active
ingredients commonly found in topical products today that may benefit from
enhanced skin permeability performance in concert with the
DehydraTECHTM technology.
The Company believes that its DehydraTECHTM
technology could drive significant innovation and improvement for the delivery
of active ingredients through topical products, transdermal patches, cosmetics
and many other skin-oriented consumer product formats. Lexaria will initiate
third-party licensing discussions for this new transdermal application of
DehyrdaTECHTM as soon as possible.
Lexaria s patented DehydraTECH technology is focused on
improved delivery methodologies of many commonly used API substances. As
such, it provides an additional layer of effectiveness that is designed to
harmonize with the intellectual property of third parties. Both patented and
generic API substances can utilize Lexaria s patented technology. Lexaria s long
term strategy is to partner with the world s leading firms as they deliver
best-of-class products to their existing large consumer groups.
Lexaria Bioscience Corp. has developed
and out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over
40 countries around the world and has patents granted in the USA and in
Australia for utilization of its DehydraTECHTM delivery technology.
Lexaria s technology provides increases in intestinal absorption rates; more
rapid delivery to the bloodstream; and important taste-masking benefits, for
orally administered bioactive molecules including cannabinoids, vitamins,
non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp)
and on Facebook http://tinyurl.com/y8vzcaam
FOR FURTHER INFORMATION PLEASE CONTACT:
Alex Blanchard, Communications Manager
NetworkNewsWire (NNW)
FORWARD-LOOKING STATEMENTS
This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements, including
but not limited to: that any additional patent protection will be realized or
that patent achievements will deliver material results. Such forward-looking
statements are estimates reflecting the Company's best judgment based upon
current information and involve a number of risks and uncertainties, and there
can be no assurance that other factors will not affect the accuracy of such
forward-looking statements. Factors which could cause actual results to differ
materially from those estimated by the Company include, but are not limited to,
government regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition, scientific discovery, the patent application
and approval process and other factors which may be identified from time to time
in the Company's public announcements and filings. There is no assurance that
existing capital is sufficient for the Company's needs or that it will be able
to raise additional capital. There is no assurance the Company will be capable
of developing, marketing, licensing, or selling edible products containing
cannabinoids or any other active ingredient. There is no assurance that any
planned corporate activity, scientific research or study, business venture,
technology licensing pursuit, patent application or allowance, consumer study,
or any initiative will be pursued, or if pursued, will be successful. There is
no assurance that any of Lexaria s postulated uses, benefits, or advantages for
the patented and patent-pending technology will in fact be realized in any
manner or in any part. No statement herein has been evaluated by the Food and
Drug Administration (FDA). Lexaria-associated products are not intended to
diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release.